At the 21st Spinal Research Annual Network Meeting, we had the pleasure of speaking with Aileen Anderson about her talk on ‘Traumatic CNS injury and the inflammatory stem cell niche’, including the obstacles involved with tissue regeneration following injury and the how this could be overcome.
What are the main challenges surrounding primary prevention trials for Alzheimer’s? Should researchers be exploring alternative avenues to amyloid-β in these trials? Take a look at our interview with Randall Bateman to find out more.
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
In this Editorial, published in the journal Future Neurology, the author discusses the need for continued funding for spinal muscular atrophy.
Genetic therapies represent a remarkable avenue for potentially slowing and preventing neurodegenerative diseases. This includes a first-in-human, gene-silencing treatment for Alzheimer’s disease. Find out more on this from Catherine Mummery.
In this video, we spoke with Henrik Zetterberg to find out how challenges with replication, reproducibility and specificity could be addressed in the field.
In this interview, Jeffrey Cummings speaks to us about the current landscape around antibody therapeutics for Alzheimer’s disease.
At the BNA Festival of Neuroscience, we had the pleasure of speaking with Barry Everitt about his talk on ‘Addiction: a compulsive interplay between drugs, cues and habits’.
In a revolutionary approach, Cognetivity (London, UK) have created a new test for detecting dementia and Alzheimer’s disease by focusing on image cognition and the brain’s ability to analyze visual information.